Evidence map›Paper›PMID 39964703›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Chemical Proteomics Reveals Human Off-Targets of Fluoroquinolone Induced Mitochondrial Toxicity.

Till Reinhardt, Yassmine El Harraoui, Alex Rothemann, Adrian T Jauch, Sigrid Müller-Deubert, Martin F Köllen, Timo Risch, Lianne Jhc Jacobs, Rolf Müller, Franziska R Traube and 5 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Till ReinhardtCenter for Functional Protein Assemblies, Department of Bioscience, TUM School of Natural Sciences, Technische Universität München, Ernst-Otto-Fischer-Straße 8, 85748, Garching, Deutschland.ORCID 0000-0003-2967-0828
Yassmine El HarraouiCenter for Functional Protein Assemblies, Department of Bioscience, TUM School of Natural Sciences, Technische Universität München, Ernst-Otto-Fischer-Straße 8, 85748, Garching, Deutschland.ORCID 0009-0009-2273-9563
Alex RothemannInstitute for Biochemistry and CECAD, University of Cologne, Köln, Deutschland.ORCID 0000-0002-9502-5360
Adrian T JauchDepartment of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-Universität München, Butenandtstraße 5-13, 81377, München, Deutschland.ORCID 0009-0005-8578-0919
Sigrid Müller-DeubertDepartment of Musculoskeletal Tissue Regeneration, Orthopaedic Hospital König-Ludwig-Haus, University of Würzburg, 97076, Würzburg, Deutschland.ORCID 0000-0002-8558-4636
Martin F KöllenCenter for Functional Protein Assemblies, Department of Bioscience, TUM School of Natural Sciences, Technische Universität München, Ernst-Otto-Fischer-Straße 8, 85748, Garching, Deutschland.ORCID 0000-0003-1611-5729
Timo RischHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Saarland University Department of Pharmacy, Campus Building E8.1, 66123, Saarbrücken, Deutschland.ORCID 0009-0003-2212-8232
Lianne Jhc JacobsInstitute for Biochemistry and CECAD, University of Cologne, Köln, Deutschland.ORCID 0000-0001-5090-601X
Rolf MüllerHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Saarland University Department of Pharmacy, Campus Building E8.1, 66123, Saarbrücken, Deutschland.ORCID 0000-0002-1042-5665
Franziska R TraubeInstitut für Biochemie und Technische Biochemie, Universität Stuttgart, 70569, Stuttgart.ORCID 0000-0002-5691-1941
Denitsa DochevaDepartment of Musculoskeletal Tissue Regeneration, Orthopaedic Hospital König-Ludwig-Haus, University of Würzburg, 97076, Würzburg, Deutschland.ORCID 0000-0002-7588-1290
Stefan ZahlerDepartment of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-Universität München, Butenandtstraße 5-13, 81377, München, Deutschland.ORCID 0000-0002-5140-7287
Jan RiemerInstitute for Biochemistry and CECAD, University of Cologne, Köln, Deutschland.ORCID 0000-0002-7574-8457
Nina C BachCenter for Functional Protein Assemblies, Department of Bioscience, TUM School of Natural Sciences, Technische Universität München, Ernst-Otto-Fischer-Straße 8, 85748, Garching, Deutschland.ORCID 0009-0001-8834-7695
Stephan A SieberCenter for Functional Protein Assemblies, Department of Bioscience, TUM School of Natural Sciences, Technische Universität München, Ernst-Otto-Fischer-Straße 8, 85748, Garching, Deutschland.ORCID 0000-0002-9400-906X

Funding

BMBF grant CellWiTaL 13N15874COST Action TENET CA22170European Union, ERC, breakingBAC 101096911Merck Future Insight Prize 2020
6 · The paper itself

Abstract

Fluoroquinolones (FQs) are an important class of potent broad-spectrum antibiotics. However, their general use is more and more limited by adverse side effects. While general mechanisms for the fluoroquinolone-associated disability (FQAD) have been identified, the underlying molecular targets of toxicity remain elusive. In this study, focusing on the most commonly prescribed FQs Ciprofloxacin and Levofloxacin, whole proteome analyses revealed prominent mitochondrial dysfunction in human cells, specifically of the complexes I and IV of the electron transport chain (ETC). Furthermore, global untargeted chemo-proteomic methodologies such as photo-affinity profiling with FQ-derived probes, as well as derivatization-free thermal proteome profiling, were applied to elucidate human protein off-targets of FQs in living cells. Accordingly, the interactions of FQs with mitochondrial AIFM1 and IDH2 have been identified and biochemically validated for their contribution to mitochondrial dysfunction. Of note, the FQ induced ETC dysfunction via AIFM1 activates the reverse carboxylation pathway of IDH2 for rescue, however, its simultaneous inhibition further enhances mitochondrial toxicity. This off-target discovery study provides unique insights into FQ toxicity enabling the utilization of identified molecular principles for the design of a safer FQ generation.

Indexed as

Anti-Bacterial AgentsFluoroquinolonesMitochondriaProteomicsHumansAnti-Bacterial AgentsFluoroquinolonesAntibioticsChemical proteomicsFluoroquinoloneHuman off-targetsMitochondrial toxicity

Identifiers

PMID39964703
PMCPMC12036814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.